<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02891915</url>
  </required_header>
  <id_info>
    <org_study_id>14-0079</org_study_id>
    <secondary_id>HHSN272201300023I</secondary_id>
    <nct_id>NCT02891915</nct_id>
  </id_info>
  <brief_title>Trial to Evaluate Beta-Lactam Antimicrobial Therapy of Community Acquired Pneumonia in Children</brief_title>
  <official_title>A Phase IV Double-Blind, Placebo-Controlled, Randomized Trial to Evaluate Short Course vs.Standard Course Outpatient Therapy of Community Acquired Pneumonia in Children (SCOUT-CAP)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>National Institute of Allergy and Infectious Diseases (NIAID)</agency>
      <agency_class>NIH</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>National Institute of Allergy and Infectious Diseases (NIAID)</source>
  <oversight_info>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a multi-center, randomized, double-blind, placebo-controlled, superiority clinical
      trial will test the effectiveness of short (5-day) vs.standard (10-day) course therapy in
      children who are diagnosed with CAP and initially treated in outpatient clinics, urgent care
      facilities, and emergency departments. Primary objective is to compare the composite overall
      outcome (Desirability of Outcome Ranking, DOOR) among children 6-71 months of age with CAP
      assigned to a strategy of short course (5 days) vs standard course (10 days) outpatient
      beta-lactam therapy at Outcome Assessment Visit #1 (Study Day 8 +/- 2 days)
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This is a multi-center, randomized, double-blind, placebo-controlled, superiority clinical
      trial evaluating short course (5 day) vs. standard course (10 day) of oral beta-lactam
      antibiotic therapy (amoxicillin, amoxicillin-clavulanate, cefdinir) for treatment of CAP in
      children 6-71 months of age who have clinically improved prior to enrollment. The study will
      randomize approximately 400 enrolled subjects to one of the two study arms (approximately 200
      children in each arm) in order to reach 360 subjects completing Outcome Assessment Visit 1.
      Subjects will be randomized (1:1) to receive either a standard course of the initially
      prescribed antibiotic (10 days) or a short course of the initially prescribed antibiotic (5
      days) plus 5 days of matching placebo. The study will recruit potential subjects from
      children who are diagnosed with CAP and who are initiated on oral beta-lactam therapy by
      healthcare providers in EDs, outpatient clinics, and urgent care centers at the study sites.
      Day -5 is defined as the date on which oral beta-lactam therapy is initiated for a diagnosis
      of CAP. Potential subjects will be identified at any time following clinical diagnosis of
      pneumonia. These subjects will be assessed for eligibility and enrolled on Day -3 to -1 of
      their initially prescribed oral beta-lactam therapy. Subjects may also be enrolled on Day 1
      (the first day of receipt of study agent) provided they have not yet received any doses of
      the healthcare provider-prescribed antibiotic therapy for that day. The Primary objective is
      to compare the composite overall outcome (Desirability of Outcome Ranking, DOOR) among
      children 6-71 months of age with CAP assigned to a strategy of short course (5 days) vs
      standard course (10 days) outpatient beta-lactam therapy at Outcome Assessment Visit #1
      (Study Day 8 +/- 2 days). The Secondary objectives are: 1) To compare the composite overall
      outcome (DOOR) among children 6-71 months of age with CAP assigned to a strategy of short
      course (5 days) vs standard course (10 days) outpatient beta-lactam therapy at Outcome
      Assessment Visit #2 (Study Day 22 +/- 3 days); 2) To compare the resolution of symptoms (a
      component of DOOR) among children 6-71 months of age with CAP assigned to a strategy of short
      course (5 days) vs standard course (10 days) outpatient beta-lactam therapy at Outcome
      Assessment Visits #1 and #2; 3) To compare the clinical response (a component of DOOR) among
      children 6-71 months of age with CAP assigned to a strategy of short course (5 days) vs
      standard course (10 days) outpatient beta-lactam therapy at Outcome Assessment Visits #1 and
      #2; 4) To compare solicited events (a component of DOOR) among children 6-71 months of age
      with CAP assigned to a strategy of short course (5 days) vs standard course (10 days)
      outpatient beta-lactam therapy at Outcome Assessment Visits #1 and #2; 5) To compare
      medically attended visits to Emergency Departments (ED) or outpatient clinics,
      hospitalizations, surgical procedures, and receipt of non-study systemic antibiotics
      (components of the clinical response) among children 6-71 months of age with CAP assigned to
      a strategy of short course (5 days) vs standard course (10 days) outpatient beta-lactam
      therapy at Outcome Assessment Visits #1 and #2
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">October 4, 2016</start_date>
  <completion_date type="Anticipated">March 1, 2019</completion_date>
  <primary_completion_date type="Anticipated">January 1, 2019</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Triple (Participant, Care Provider, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Desirability of Outcome Ranking (DOOR)</measure>
    <time_frame>Outcome Assessment Visit 1 (Study Day 8 +/- 2 days)</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Adequate clinical response rates (a component of DOOR)</measure>
    <time_frame>Outcome Assessment Visit 1 (Study Day 8 +/- 2 days), Outcome Assessment Visit 2 (Study Day 22 +/- 3 days)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Desirability of Outcome Ranking (DOOR)</measure>
    <time_frame>Outcome Assessment Visit 2 (Study Day 22 +/- 3 days)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Frequency of solicited events</measure>
    <time_frame>Outcome Assessment Visit 1 (Study Day 8 +/- 2 days), Outcome Assessment Visit 2 (Study Day 22 +/- 3 days)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Receipt of non-study systemic antibiotics for all causes during medically attended visits</measure>
    <time_frame>Outcome Assessment Visit 1 (Study Day 8 +/- 2 days), Outcome Assessment Visit 2 (Study Day 22 +/- 3 days)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Receipt of non-study systemic antibiotics for persistent or worsening pneumonia during medically attended visits</measure>
    <time_frame>Outcome Assessment Visit 1 (Study Day 8 +/- 2 days), Outcome Assessment Visit 2 (Study Day 22 +/- 3 days)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Resolution of symptoms (a component of DOOR)</measure>
    <time_frame>Outcome Assessment Visit 1 (Study Day 8 +/- 2 days), Outcome Assessment Visit 2 (Study Day 22 +/- 3 days)</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">400</enrollment>
  <condition>Pneumonia</condition>
  <arm_group>
    <arm_group_label>Short</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>200 subjects will receive a short course of the initially prescribed antibiotic for 5 days plus 5 days of matching placebo</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Standard</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>200 subjects will receive a standard course of the initially prescribed antibiotic( Amoxicillin, Amoxicillin-Clavulanate, Cefdinir) for 10 days</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Amoxicillin</intervention_name>
    <description>Amoxicillin is an aminopenicillin antibiotic</description>
    <arm_group_label>Short</arm_group_label>
    <arm_group_label>Standard</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Amoxicillin-clavulanate</intervention_name>
    <description>A fixed-ratio combination of amoxicillin trihydrate, an aminopenicillin, and potassium clavulanate, a beta-lactamase inhibitor, used to treat a broad-spectrum of bacterial infections, especially resistant strains.</description>
    <arm_group_label>Short</arm_group_label>
    <arm_group_label>Standard</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Cefdinir</intervention_name>
    <description>Cefdinir is a cephalosporin antibiotic used to treat bacterial infections in many different parts of the body.</description>
    <arm_group_label>Short</arm_group_label>
    <arm_group_label>Standard</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Placebo</description>
    <arm_group_label>Short</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Age 6 - 71 months

          2. Provider diagnosis of CAP and prescription of antibiotic therapy with amoxicillin,
             amoxicillin-clavulanate, or cefdinir

             - amoxicillin or amoxicillin-clavulanate prescribed at a amoxicillin dose of 60
             mg/kg/day

             -- cefdinir prescribed at a minimum dose of 10 mg/kg/day

          3. Parental report of clinical improvement

             - based on lack of either subjective or known fever temperature &gt;/= 38.3Â°C in the
             preceding 24 hours; current respiratory rate no greater than 50 breaths/minute (&lt;2
             years of age) or breaths/minute (= / &gt; 2 years of age); and current grade of cough &lt; 3

          4. Ability of a parent or guardian to understand and comply with the study procedures and
             be available for all study visits

          5. Signed written informed consent by a parent or guardian

        Exclusion Criteria:

        1. Treatment with any systemic antibiotic therapy within 7 days before the diagnosis of CAP
        2. Initial therapy for CAP with combination antibiotic therapy

          -  amoxicillin, amoxicillin/clavulanate or cefdinir plus one or more additional oral,
             intravenous, or intramuscular antibiotics 3. History of anaphylaxis or severe drug
             allergy to amoxicillin, if prescribed amoxicillin or amoxicillin/clavulanic acid; or
             oral cephalosporin antibiotics (except cefaclor), if prescribed cefdinir 4. Presence
             of concomitant bacterial infection that requires &gt; 5 days of antibiotic therapy 5.
             Radiographic findings (where applicable) of complicated pneumonia at presentation or
             any subsequent chest radiograph up to the time of enrollment

          -  clinically significant pleural effusion, lung abscess, or pneumatocele 6.
             Hospitalization for pneumonia during Day -5 to -1 of antibiotic therapy for CAP

          -  subjects who require serial clinical assessments, but are discharged within 24 hours
             will not be considered hospitalized and will not satisfy this exclusion criterion 7.
             Pneumonia due to S. aureus or group A streptococcus documented by positive blood
             culture or PCR, at the time of enrollment 8. History of pneumonia within the previous
             6 months 9. History of persistent asthma within the previous 6 months or current acute
             asthma exacerbation

          -  persistent asthma is defined as receiving daily asthma maintenance therapy such as
             inhaled corticosteroids, cromolyn, theophylline, or leukotriene receptor antagonists

             -- acute asthma exacerbation is defined as receiving concomitant bronchodilator
             therapy and systemic corticosteroids 10. Provider-diagnosis of aspiration pneumonia,
             bronchiolitis, or bronchitis 11. Surgery or other invasive procedures of the upper or
             lower airway (e.g., bronchoscopy, laryngoscopy) with general anesthesia or
             hospitalization &lt;/=7 days before diagnosis of CAP 12. History of an underlying chronic
             medical condition

          -  including chronic heart disease, chronic lung disease (except asthma), congenital
             anomalies of the airways or lung, cystic fibrosis, chronic renal disease including
             nephrotic syndrome, protein-losing enteropathy of any cause, severe malnutrition,
             genetic syndromes, neurocognitive disorders, or metabolic disorders (including
             phenylketonuria) 13. History of a condition that compromises the immune system

          -  HIV infection, primary immunodeficiency, anatomic or functional asplenia; receipt of a
             hematopoietic stem cell or solid organ transplant at any time; receipt of
             immunosuppressive therapy including chemotherapeutic agents, biologic agents,
             antimetabolites or radiation therapy during the past 12 months; or daily use of
             systemic corticosteroids for more than 7 consecutive days during the past 14 days 14.
             Any other condition that in the judgment of the investigator precludes participation
             because it could affect the safety of the subject 15. Current enrollment in another
             clinical trial of an investigational agent 16. Previous enrollment in this trial
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>6 Months</minimum_age>
    <maximum_age>71 Months</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Clarence Buddy Creech</last_name>
    <phone>16159362186</phone>
    <email>buddy.creech@vanderbilt.edu</email>
  </overall_contact>
  <location>
    <facility>
      <name>University of Alabama - Children's of Alabama - Infectious Diseases/Virology</name>
      <address>
        <city>Birmingham</city>
        <state>Alabama</state>
        <zip>35233-1711</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Arkansas Children's Hospital - Infectious Diseases</name>
      <address>
        <city>Little Rock</city>
        <state>Arkansas</state>
        <zip>72202-3500</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>University of Louisville School of Medicine - Norton Children's Hospital - Infectious Diseases</name>
      <address>
        <city>Louisville</city>
        <state>Kentucky</state>
        <zip>40202</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Washington University School of Medicine in St. Louis - Infectious Diseases</name>
      <address>
        <city>Saint Louis</city>
        <state>Missouri</state>
        <zip>63110-1010</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Duke Human Vaccine Institute - Duke Clinical Vaccine Unit</name>
      <address>
        <city>Durham</city>
        <state>North Carolina</state>
        <zip>27704</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Cincinnati Children's Hospital Medical Center - Infectious Diseases</name>
      <address>
        <city>Cincinnati</city>
        <state>Ohio</state>
        <zip>45229-3039</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Completed</status>
  </location>
  <location>
    <facility>
      <name>Children's Hospital of Philadelphia - The Center for Pediatric Clinical Effectiveness</name>
      <address>
        <city>Philadelphia</city>
        <state>Pennsylvania</state>
        <zip>19104-3309</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Children's Hospital of Pittsburgh of UPMC - General Academic Pediatric</name>
      <address>
        <city>Pittsburgh</city>
        <state>Pennsylvania</state>
        <zip>15213-3205</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Vanderbilt University - Pediatric - Vanderbilt Vaccine Research Center</name>
      <address>
        <city>Nashville</city>
        <state>Tennessee</state>
        <zip>37232-2573</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>April 5, 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>September 1, 2016</study_first_submitted>
  <study_first_submitted_qc>September 1, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 8, 2016</study_first_posted>
  <last_update_submitted>April 26, 2018</last_update_submitted>
  <last_update_submitted_qc>April 26, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">April 27, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Antimicrobial</keyword>
  <keyword>Beta-Lactam</keyword>
  <keyword>Pneumonia</keyword>
  <keyword>Short Course</keyword>
  <keyword>Standard Course</keyword>
  <keyword>Therapy</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Pneumonia</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Anti-Bacterial Agents</mesh_term>
    <mesh_term>Amoxicillin</mesh_term>
    <mesh_term>Clavulanic Acid</mesh_term>
    <mesh_term>Clavulanic Acids</mesh_term>
    <mesh_term>beta-Lactams</mesh_term>
    <mesh_term>Amoxicillin-Potassium Clavulanate Combination</mesh_term>
    <mesh_term>Cefdinir</mesh_term>
    <mesh_term>Antibiotics, Antitubercular</mesh_term>
    <mesh_term>Anti-Infective Agents</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

